Compare Incyte Corporation (INCY) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Verisign, Inc. — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Verisign, Inc. for 123 Days on average.
| INCY | VRSN | |
|---|---|---|
Market Cap | $22.85B | $26.92B |
Volume | 1,927,029 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $129.93 | $310.00 |
52-Week Low | $83.80 | $211.49 |
Typical Hold Time | 33 Days | 123 Days |
Enterprise Value | $18.35B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
VeriSign (VRSN) trades at $303.74, up 3.24% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 49.77% net income margin and consistent revenue growth, reaching $1.66B in 2025. Recent news includes an upcoming Q3 2026 earnings call and insider selling by the CEO, while institutional buying from firms like BlackRock signals confidence. A class-action antitrust lawsuit filed in September 2026 poses a regulatory risk.
The investment outlook is positive, driven by analyst consensus favoring a buy rating with a $348 price target, implying 15% upside. Key opportunities include AI-driven domain growth and a pending .com price increase. Risks involve the antitrust litigation, competitive pressures, and reliance on domain registry revenues. Earnings momentum is mixed, with Q2 2026 missing estimates but Q1 beating expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
